Search

Your search keyword '"Barrett, Michael"' showing total 1,435 results
Start Over Author "Barrett, Michael" Publication Year Range Last 10 years
1,435 results on '"Barrett, Michael"'

4. An Exploration of an Interprofessional Embedded Educational Model between Occupational Therapy and Industrial Design: A Qualitative Hermeneutical Phenomenological Inquiry

Author

Barrett, Michael P., McNabb, Sarah A., Mollo, Kimberly S., Schneider, Eric, and Corlett, Tod

Abstract

Background: Interprofessional education represents an opportunity for healthcare and design students to deepen their understanding of users and enhance skill development through collaborative experiences. Embedding these collaborative experiences within entire curricula moves the notion of experiential learning from stand-alone projects towards the nuanced learning opportunities only available with sustained regular contact. Methods: Occupational therapy doctoral students were integrated into two cohorts of Master of Industrial Design (MSID) student courses for one academic year. Interviews were conducted to gather qualitative information about the student experiences, which were then transcribed, coded, and analyzed for themes. Results: Industrial design students reported positive learning experiences when collaborating with occupational therapy students that deepened understanding of user-centeredness, improved communication skills, and more well-developed student projects than would have been possible alone. Conclusion: The contribution of occupational therapy and industrial design students into collaborative courses and projects may result in a greater topical understanding and more advanced skill development than any singular discipline's program. Further research to compare development against students without collaborative experiences is needed to understand the magnitude of a collaboration's potential impact.

Published
2023
Full Text
View/download PDF

5. T2-Weighted MRI Radiomic Features Predict Prostate Cancer Presence and Eventual Biochemical Recurrence.

Author

Duenweg, Savannah, Bobholz, Samuel, Barrett, Michael, Lowman, Allison, Winiarz, Aleksandra, Nath, Biprojit, Stebbins, Margaret, Bukowy, John, Iczkowski, Kenneth, Jacobsohn, Kenneth, Vincent-Sheldon, Stephanie, and LaViolette, Peter

Subjects
Gleason pattern, biochemical recurrence, mp-MRI, prostate cancer, radiomic features
Abstract

Prostate cancer (PCa) is the most diagnosed non-cutaneous cancer in men. Despite therapies such as radical prostatectomy, which is considered curative, distant metastases may form, resulting in biochemical recurrence (BCR). This study used radiomic features calculated from multi-parametric magnetic resonance imaging (MP-MRI) to evaluate their ability to predict BCR and PCa presence. Data from a total of 279 patients, of which 46 experienced BCR, undergoing MP-MRI prior to surgery were assessed for this study. After surgery, the prostate was sectioned using patient-specific 3D-printed slicing jigs modeled using the T2-weighted imaging (T2WI). Sectioned tissue was stained, digitized, and annotated by a GU-fellowship trained pathologist for cancer presence. Digitized slides and annotations were co-registered to the T2WI and radiomic features were calculated across the whole prostate and cancerous lesions. A tree regression model was fitted to assess the ability of radiomic features to predict BCR, and a tree classification model was fitted with the same radiomic features to classify regions of cancer. We found that 10 radiomic features predicted eventual BCR with an AUC of 0.97 and classified cancer at an accuracy of 89.9%. This study showcases the application of a radiomic feature-based tool to screen for the presence of prostate cancer and assess patient prognosis, as determined by biochemical recurrence.

Published
2023

8. A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer

Author

Antal, Corina E, Oh, Tae Gyu, Aigner, Stefan, Luo, En-Ching, Yee, Brian A, Campos, Tania, Tiriac, Hervé, Rothamel, Katherine L, Cheng, Zhang, Jiao, Henry, Wang, Allen, Hah, Nasun, Lenkiewicz, Elizabeth, Lumibao, Jan C, Truitt, Morgan L, Estepa, Gabriela, Banayo, Ester, Bashi, Senada, Esparza, Edgar, Munoz, Ruben M, Diedrich, Jolene K, Sodir, Nicole M, Mueller, Jasmine R, Fraser, Cory R, Borazanci, Erkut, Propper, David, Von Hoff, Daniel D, Liddle, Christopher, Yu, Ruth T, Atkins, Annette R, Han, Haiyong, Lowy, Andrew M, Barrett, Michael T, Engle, Dannielle D, Evan, Gerard I, Yeo, Gene W, Downes, Michael, and Evans, Ronald M

Subjects
Biochemistry and Cell Biology, Biomedical and Clinical Sciences, Biological Sciences, Rare Diseases, Digestive Diseases, Pancreatic Cancer, Genetics, Cancer, Aetiology, 2.1 Biological and endogenous factors, Male, Animals, Mice, RNA, Epigenesis, Genetic, Regulatory Sequences, Nucleic Acid, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Methyltransferases, RNA-Binding Proteins
Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy in need of new therapeutic options. Using unbiased analyses of super-enhancers (SEs) as sentinels of core genes involved in cell-specific function, here we uncover a druggable SE-mediated RNA-binding protein (RBP) cascade that supports PDAC growth through enhanced mRNA translation. This cascade is driven by a SE associated with the RBP heterogeneous nuclear ribonucleoprotein F, which stabilizes protein arginine methyltransferase 1 (PRMT1) to, in turn, control the translational mediator ubiquitin-associated protein 2-like. All three of these genes and the regulatory SE are essential for PDAC growth and coordinately regulated by the Myc oncogene. In line with this, modulation of the RBP network by PRMT1 inhibition reveals a unique vulnerability in Myc-high PDAC patient organoids and markedly reduces tumor growth in male mice. Our study highlights a functional link between epigenetic regulation and mRNA translation and identifies components that comprise unexpected therapeutic targets for PDAC.

Published
2023

9. The International Education Index: A Global Approach to Education Policy Analysis, Performance and Sustainable Development

Author

Clark, Serena, Gallagher, Ellen, Boyle, Neasa, Barrett, Michael, Hughes, Corey, O'Malley, Niamh, Ebuenyi, Ikenna, Marshall, Kevin, and O'Sullivan, Katriona

Abstract

Before the COVID-19 pandemic, the world struggled to address growing educational inequalities and fulfil the commitment to Sustainable Development Goal 4, which seeks to ensure inclusive and equitable quality education and promote lifelong learning opportunities for all. The pandemic has exacerbated these inequalities and changed how education functions, moving to online and hybrid methods. The challenges in global education highlighted and worsened by the pandemic make it necessary to re-evaluate education systems and the policies in place to support access, quality and equal opportunity. This article focuses on analysing education policies at a national level. It tests a pilot policy analysis tool, the International Education Index (IEI), developed as a starting point to begin this reconsideration and create an accessible and comprehensive way to evaluate national education systems to inform decision-making and policies in the new context. This research uses Ireland and Northern Ireland to test the IEI pilot tool. The IEI consists of 54 questions across nine indicators, including institutional frameworks, education strategies, digital skills and infrastructure, twenty-first century skills, access to basic social services, adherence to international standards, legal frameworks, data gathering and availability and international partnerships. Countries can score 108 points to be categorised as having developed, emerging or nascent national education systems. Ireland scored 94 and Northern Ireland 81, indicating that they have developed national education systems.

Published
2023
Full Text
View/download PDF

10. Chapter 48 In Vivo Bioluminescence Imaging to Assess Compound Efficacy Against Trypanosoma brucei

Author

Ritchie, Ryan, Barrett, Michael, Mottram, Jeremy, and Myburgh, Elmarie

Subjects
Firefly luciferase, Trypanosoma brucei brucei, In vivo imaging, Bioluminescence, bic Book Industry Communication::P Mathematics & science::PS Biology, life sciences
Abstract

Traditional animal models for human African trypanosomiasis rely on detecting Trypanosoma brucei brucei parasitemia in the blood. Testing the efficacy of new compounds in these models is cumbersome because it may take several months after treatment before surviving parasites become detectable in the blood. To expedite compound screening, we have used a Trypanosoma brucei brucei GVR35 strain expressing red-shifted firefly luciferase to monitor parasite distribution in infected mice through noninvasive wholebody bioluminescence imaging. This protocol describes the infection and in vivo bioluminescence imaging of mice to assess compound efficacy against T. brucei during the two characteristic stages of disease, the hemolymphatic phase (stage 1) and the encephalitic or central nervous system phase (stage 2).

Published
2020
Full Text
View/download PDF

19. PDJ amplicon in triple negative breast cancer

Author

Roesler, Alexander S., Malasi, Smriti, Koslosky, Lori, Hartmayer, Peter, Naab, Tammey J., Carter, Jodi M., Zahrieh, David, Hillman, David, Leon-Ferre, Roberto A., Couch, Fergus J., Goetz, Matthew P., Anderson, Karen S., Pockaj, Barbara A., and Barrett, Michael T.

Published
2023
Full Text
View/download PDF

22. Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas

Author

Lenkiewicz, Elizabeth, Malasi, Smriti, Hogenson, Tara L, Flores, Luis F, Barham, Whitney, Phillips, William J, Roesler, Alexander S, Chambers, Kendall R, Rajbhandari, Nirakar, Hayashi, Akimasa, Antal, Corina E, Downes, Michael, Grandgenett, Paul M, Hollingsworth, Michael A, Cridebring, Derek, Xiong, Yuning, Lee, Jeong-Heon, Ye, Zhenqing, Yan, Huihuang, Hernandez, Matthew C, Leiting, Jennifer L, Evans, Ronald M, Ordog, Tamas, Truty, Mark J, Borad, Mitesh J, Reya, Tannishtha, Von Hoff, Daniel D, Fernandez-Zapico, Martin E, and Barrett, Michael T

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Bioinformatics and Computational Biology, Genetics, Oncology and Carcinogenesis, Rare Diseases, Biotechnology, Cancer, Digestive Diseases, Human Genome, Pancreatic Cancer, Aetiology, 2.1 Biological and endogenous factors, Carcinoma, Adenosquamous, Carcinoma, Pancreatic Ductal, Chromatin, Epigenome, Humans, Mutation, Organoids, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Receptor, Fibroblast Growth Factor, Type 1, Single-Cell Analysis, Smad4 Protein, Exome Sequencing, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

Adenosquamous cancer of the pancreas (ASCP) is a subtype of pancreatic cancer that has a worse prognosis and greater metastatic potential than the more common pancreatic ductal adenocarcinoma (PDAC) subtype. To distinguish the genomic landscape of ASCP and identify actionable targets for this lethal cancer, we applied DNA content flow cytometry to a series of 15 tumor samples including five patient-derived xenografts (PDX). We interrogated purified sorted tumor fractions from these samples with whole-genome copy-number variant (CNV), whole-exome sequencing, and Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) analyses. These identified a variety of somatic genomic lesions targeting chromatin regulators in ASCP genomes that were superimposed on well-characterized genomic lesions including mutations in TP53 (87%) and KRAS (73%), amplification of MYC (47%), and homozygous deletion of CDKN2A (40%) that are common in PDACs. Furthermore, a comparison of ATAC-seq profiles of three ASCP and three PDAC genomes using flow-sorted PDX models identified genes with accessible chromatin unique to the ASCP genomes, including the lysine methyltransferase SMYD2 and the pancreatic cancer stem cell regulator RORC in all three ASCPs, and a FGFR1-ERLIN2 fusion associated with focal CNVs in both genes in a single ASCP. Finally, we demonstrate significant activity of a pan FGFR inhibitor against organoids derived from the FGFR1-ERLIN2 fusion-positive ASCP PDX model. Our results suggest that the genomic and epigenomic landscape of ASCP provide new strategies for targeting this aggressive subtype of pancreatic cancer. SIGNIFICANCE: These data provide a unique description of the ASCP genomic and epigenomic landscape and identify candidate therapeutic targets for this dismal cancer.

Published
2020

23. An Evaluation of the Utility of Big Data to Supplement Cancer Treatment Information: Linkage Between IQVIA Pharmacy Database and the Surveillance, Epidemiology, and End Results Program.

Author

Tran, Quyen, Warren, Joan L, Barrett, Michael J, Annett, Dave, Marth, Melissa, Cress, Rosemary D, Deapen, Dennis, Glaser, Sally L, Gomez, Scarlett L, Schwartz, Stephen M, Li, Christopher I, Wu, Xiao-Cheng, Enewold, Lindsey, Harlan, Linda C, Rivera, Donna R, Winn, Deborah M, Penberthy, Lynne, and Cronin, Kathleen A

Subjects
Health Services, Breast Cancer, Hematology, Rare Diseases, Cancer, Clinical Research, Good Health and Well Being, Aged, Big Data, Female, Humans, Male, Medicare, Middle Aged, Neoplasms, Pharmacy, SEER Program, United States, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Oral anticancer medications (OAMs) are increasingly utilized. We evaluated the representativeness and completeness of IQVIA, a large aggregator of pharmacy data, for breast cancer, colon cancer, chronic myeloid leukemia, and myeloma cases diagnosed in six Surveillance, Epidemiology, and End Results Program (SEER) registries between 2007 and 2011. Patient's SEER and SEER-Medicare data were linked and compared with IQVIA pharmacy data from 2006 to 2012 for specific OAMs. Overall, 67.6% of SEER cases had a pharmacy claim in IQVIA during the treatment assessment window. This varied by location, race and ethnicity, and insurance status. IQVIA consistently identified fewer cases who received an OAM of interest than SEER-Medicare. The difference was least pronounced for breast cancer agents and most pronounced for myeloma agents. The IQVIA pharmacy database included a large portion of persons in the SEER areas. Future studies should assess receipt of OAMs for other cancer sites and in different SEER registries.

Published
2020

24. Patterns of Care and Costs for Older Patients With Colorectal Cancer at the End of Life: Descriptive Study of the United States and Canada.

Author

Bremner, Karen E, Yabroff, K Robin, Coughlan, Diarmuid, Liu, Ning, Zeruto, Christopher, Warren, Joan L, de Oliveira, Claire, Mariotto, Angela B, Lam, Clara, Barrett, Michael J, Chan, Kelvin K-W, Hoch, Jeffrey S, and Krahn, Murray D

Subjects
Colo-Rectal Cancer, Health Services, Clinical Research, Digestive Diseases, Cancer, Aged, Aged, 80 and over, Canada, Colorectal Neoplasms, Female, Humans, Male, Terminal Care, United States
Abstract

PurposeEnd-of-life (EOL) cancer care is costly, with challenges regarding intensity and place of care. We described EOL care and costs for patients with colorectal cancer (CRC) in the United States and the province of Ontario, Canada, to inform better care delivery.MethodsPatients diagnosed with CRC from 2007 to 2013, who died of any cancer from 2007 to 2013 at age ≥ 66 years, were selected from the US SEER cancer registries linked to Medicare claims (n = 16,565) and the Ontario Cancer Registry linked to administrative health data (n = 6,587). We estimated total and resource-specific costs (2015 US dollars) from public payer perspectives over the last 360 days of life by 30-day periods, by stage at diagnosis (0-II, III, IV).ResultsIn all months, especially 30 days before death, higher percentages of SEER-Medicare than Ontario patients received chemotherapy (15.7% v 8.0%), and imaging tests (39.4% v 31.1%). A higher percentage of Ontario patients were hospitalized (62.5% v 51.0%), but 43.2% of hospitalized SEER-Medicare patients had intensive care unit (ICU) admissions versus 17.9% of hospitalized Ontario patients. Cost differences between cohorts were greater for patients with stage IV disease. In the last 30 days, mean total costs for patients with stage IV disease were $15,881 (SEER-Medicare) and $12,034 (Ontario) versus $19,354 and $17,312 for stage 0-II. Hospitalization costs were higher for SEER-Medicare patients ($11,180 v $9,434), with lower daily hospital costs in Ontario ($1,067 v $2,004).ConclusionThese findings suggest opportunities for reducing chemotherapy and ICU use in the United States and hospitalizations in Ontario.

Published
2020

29. FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations

Author

Uson Junior, Pedro Luiz Serrano, DeLeon, Thomas T., Bogenberger, James M., Pai, Rish K., Kosiorek, Heidi E., Yin, Jun, Ahn, Daniel H., Sonbol, Mohammad Bassam, Bekaii-Saab, Tanios, Mansfield, Aaron S., Buetow, Kenneth, Gores, Gregory J., Smoot, Rory, Vasmatzis, George, Kipp, Benjamin R., Mahipal, Amit, Baker, Alexander T., Babiker, Hani, Barro, Oumar, Dumbauld, Chelsae, Zhou, Yumei, Aslam, Faaiq N., Barrett, Michael, Jacobs, Bertram, Meurice, Nathalie, Arora, Mansi, Petit, Joachim, Elliott, Natalie, Nagalo, Bolni, Salomao, Marcela A., and Borad, Mitesh J.

Published
2022
Full Text
View/download PDF

34. Applying clinical decision aids for the assessment and management of febrile infants presenting to emergency care in the UK and Ireland: Febrile Infant Diagnostic Assessment and Outcome (FIDO) Study protocol.

Author

Umana, Etimbuk, Mills, Clare, Norman-Bruce, Hannah, Wilson, Kathryn, Mitchell, Hannah, McFetridge, Lisa, Woolfall, Kerry, Lynn, Fiona A., McKeeman, Gareth, Foster, Steven, Barrett, Michael, Roland, Damian, Lyttle, Mark D., Watson, Chris, and Waterfield, Thomas

Published
2024
Full Text
View/download PDF

37. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial

Author

Soiza, Roy L., Brittain-Long, Robin, Scicluna, Chiara, Edwards, Carole, Mackay, Lynn, D'Allesandro, Mariella, Nicol, Amy, Norris, Karen, Mann, Sandra, Lawrence, Heather, Valentine, Ruth, Viljoen, Marianne Elizabeth, Pretswell, Carol H., Nicholls, Helen, Munsoor, Imrozia, Meyrick, Agnieszka, Kyriakidou, Christina, Iyengar, Shalini, Jamal, Arham, Richards, Nick, Price, Helen, Rowbotham, Bridie, Bird, Danielle, Smith, Karen, Littler, Olga, Fielding, Kirsty, Townsend-Rose, Anna, Miller, Karen, Davis, Jessica, Elliot-Garwood, Alison, Trottier, Lauren, Edwards, Paul, McFarland, Margaret, Osanlou, Orod, Longshaw, Laura, Stockport, Jane, Grundy, Lynne, Broad, Katharine Lucy, Regan, Karen, Storton, Kim, Ryan-Wakeling, Declan, Wilson, Brad, Munisamy, Malathy, Wright, John, Shenoy, Anil, English, Beverley, Brear, Lucy, Cicconi, Paola, Boffito, Marta, Milinkovic, Ana, Byrne, Ruth, Movahedi, Roya, Housman, Rosalie, Kara, Naveed, Brown, Ellen, Cipriani, Andrea, Attenburrow, Mary-Jane, Smith, Katharine A., Packham, Jonathan, Sparrow, Geoff, Smith, Richard, Rosier, Josephine M., Saja, Khalid, Nago, Nyasha, Camilleri, Brian, Immanuel, Anita, Hamblin, Mike, Osagie, Rawlings, Mohan, Mahalakshmi, Floyd, Hilary, Goddard, Suzanne, Mutgi, Sanjay, Evans, John, McKeon, Sean, Vilimiene, Neringa, Chicano, Rosavic, Hayre, Rachel, Pandaan, Alice, Henshall, Catherine, Serrano, Sonia, Mazzella, Andrea, Rajeswaran, Thurkka, Mathew, Moncy, Bisnauthsing, Karen, Bremner, Laura, Fok, Henry, Morselli, Franca, Cinardo, Paola, Merrick, Blair, Sowole, Lucy, Broadhead, Samantha, Palmer, Natalie, Cordle, Jessica, Goldsmith, Jaimie Wilson, Cooney, Enya, Jackson, Beth, Jayatilleke, Thilina, Cheng, Zelda, Helliwell, Toby, Chudyk, Adrian, Giemza, Rafaela, Villajin, John Lord, Yogo, Noah, Makanju, Esther, Dulawan, Pearl, Nagra, Deepak, Buazon, April, Russell, Alice, Bird, Georgie, Heer, Amardeep, Sarmiento, Rex, Sanghera, Balraj, Mullin, Melanie, Champion, Adam, Bevan, Aisling, Iqbal, Kinzah, Johnson, Alshia, Clark, Rebecca, Shaw, Sarah, Shaw, Steven, Chalk, Amanda, Lovatt, Martin, Lillicrap, Caroline, Parker, Angela, Hansel, Jan, Wong, Zhi, Gan, Galvin, Tuma, Eyad, Minton, Jane, Murira, Jennifer, Saman, Razan, Hall, Alistair, Holliday, Kyra, Khan, Zara, Calderwood, James, Twigg, George, Baker, Helena, Corrigan, Julie, Houseman, Katy, Raguvanshi, Subhra, Heining, Dominic, Weddell, Jake, Glaves, Liz, Thompson, Kim, Davies, Francis, Lambley Burke, Ruth, Thomson, Emma C., Saralaya, Dinesh, Berry, Lisa, Hopewell, Nancy, Gerdes, Leigh, Pacurar, Mihaela, Faust, Saul N., Turner, Jeremy, Jeanes, Christopher, Cooper, Adele, Keshet-Price, Jocelyn, Coke, Lou, Cambell-Kelly, Melissa, Dhatariya, Ketan, Williams, Claire, Marks, Georgina, Sudbury, James, Rodolico, Lisa, Bradley, Judy, Carr, Sharon, Martin, Roisin, Madden, Angelina, Biagioni, Paul, McKenna, Sonia, Clinton, Alison, O'Kane, Maurice, Carter, Justin, Dewhurst, Matthew, Wetherill, Bill, Hoggarth, Thandiwe, Collins, Katrina Lennon, Chowdhury, Marie, Nathoo, Adil, Heinen, Anna, MacDonald, Orla, Hurducas, Claudia, Cifuentes, Liliana, Gill, Harjeevan, Gibson, Andy, West, Raha, Ewing, Jane, Blacow, Rachel, Haughney, John, MacDonald, Jonathan, Seenan, John Paul, Webb, Stewart, O'Leary, Colin, Muir, Scott, White, Beth, Ritchie, Neil, McAuley, Daniel F., Stewart, Jonathan, D'Alessandro, Mariella, Lakeman, Nicki, Purandare, Laura, Browne, Duncan, Tucker, David, Luck, Peter, Everden, Angharad, Trembath, Lisa, Visick, Michael, Morley, Nick, Reid, Laura, Chenoweth, Helen, Maclean, Kirsty, Sheridan, Ray P., Burden, Tom, Lunt, Craig Francis, Todd, Shirley, Estcourt, Stephanie, Pearce, Jasmine Marie, Wilkins, Suzanne, Love-Rouse, Cathryn, Torok-Pollok, Eva, Youle, Mike, Madge, Sara, Solomon, Danielle, Nandani, Aarti, North, Janet M., Hemat, Nargis, Newport, Rachel, Kalra, Philip A., Chukwu, Chukwuma, Wickens, Olivia, O'Loughlin, Vikki, Mistry, Hema, Harrison, Louise, Oliver, Robert, Peers, Anne-Marie, Zadik, Jess, Doyle, Katie, Chadwick, David R., Colling, Kerry, Wroe, Caroline, Branch, Marie, Chilvers, Alison, Essex, Sarah, Stone, Mark, San Francisco Ramos, Alberto, Beales, Emily, Bird, Olivia, Danos, Zsofia, Fofie, Hazel, Hultin, Cecilia, Ikram, Sabina, Mabesa, Fran, Mescall, Aoife, Pereira, Josyanne, Pearce, Jennifer, Sutton, Natalina, Snashall, Emma, Baxter, David Neil, Bennett, Sara, Suggitt, Debbie, Hughes, Kerry, Woodyatt, Wiesia, Beacon, Lynsey, Kent, Alissa, Cooper, Chris, Rudic, Milan, Tunstall, Simon, Jackson, Matthew, Hombersley, Claire, Moore, Patrick, Cutts, Rebecca, Higham, Andrew, Bukhari, Marwan, Elnaggar, Mohamed, Glover, Michelle, Richardson, Fiona, Dent, Alexandra, Mirza, Shahzeb, Ark, Rajiv, Han, Jennie, Hope, Suzy V., Mitchelmore, Philip J., Osanlou, Rostam, Freedman, Andrew, Cooper, Alison, Burton, Katherine, Katechia, Kashyap, Barrett, Michael, Salkeld, Jo, Hill, Natalie, Lee, Nathaniel, Perkins, Jon, Fox, Polly, Toback, Seth, Galiza, Eva, Cosgrove, Catherine, Galloway, James, Goodman, Anna L, Swift, Pauline A, Rajaram, Sankarasubramanian, Graves-Jones, Alison, Edelman, Jonathan, Burns, Fiona, Minassian, Angela M, Cho, Iksung, Kumar, Lakshmi, Plested, Joyce S, Rivers, E Joy, Robertson, Andreana, Dubovsky, Filip, Glenn, Greg, and Heath, Paul T

Published
2022
Full Text
View/download PDF

39. Supplementary Figure 6 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer

Author

Kase, Adam M., primary, Gleba, Justyna, primary, Miller, James L., primary, Miller, Erin, primary, Petit, Joachim, primary, Barrett, Michael T., primary, Zhou, Yumei, primary, Parent, Ephraim E., primary, Cai, Hancheng, primary, Knight, Joshua A., primary, Orme, Jacob, primary, Reynolds, Jordan, primary, Durham, William F., primary, Metz, Thomas M., primary, Meurice, Nathalie, primary, Edenfield, Brandy, primary, Alasonyalilar Demirer, Aylin, primary, Bilgili, Ahmet, primary, Hickman, Peyton G., primary, Pawlush, Matthew L., primary, Marlow, Laura, primary, Wickland, Daniel P., primary, Tan, Winston, primary, and Copland, John A., primary

Published
2024
Full Text
View/download PDF

40. Supplementary Figure 4 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer

Author

Kase, Adam M., primary, Gleba, Justyna, primary, Miller, James L., primary, Miller, Erin, primary, Petit, Joachim, primary, Barrett, Michael T., primary, Zhou, Yumei, primary, Parent, Ephraim E., primary, Cai, Hancheng, primary, Knight, Joshua A., primary, Orme, Jacob, primary, Reynolds, Jordan, primary, Durham, William F., primary, Metz, Thomas M., primary, Meurice, Nathalie, primary, Edenfield, Brandy, primary, Alasonyalilar Demirer, Aylin, primary, Bilgili, Ahmet, primary, Hickman, Peyton G., primary, Pawlush, Matthew L., primary, Marlow, Laura, primary, Wickland, Daniel P., primary, Tan, Winston, primary, and Copland, John A., primary

Published
2024
Full Text
View/download PDF

41. Data from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer

Author

Kase, Adam M., primary, Gleba, Justyna, primary, Miller, James L., primary, Miller, Erin, primary, Petit, Joachim, primary, Barrett, Michael T., primary, Zhou, Yumei, primary, Parent, Ephraim E., primary, Cai, Hancheng, primary, Knight, Joshua A., primary, Orme, Jacob, primary, Reynolds, Jordan, primary, Durham, William F., primary, Metz, Thomas M., primary, Meurice, Nathalie, primary, Edenfield, Brandy, primary, Alasonyalilar Demirer, Aylin, primary, Bilgili, Ahmet, primary, Hickman, Peyton G., primary, Pawlush, Matthew L., primary, Marlow, Laura, primary, Wickland, Daniel P., primary, Tan, Winston, primary, and Copland, John A., primary

Published
2024
Full Text
View/download PDF

42. Supplementary Figure 1 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer

Author

Kase, Adam M., primary, Gleba, Justyna, primary, Miller, James L., primary, Miller, Erin, primary, Petit, Joachim, primary, Barrett, Michael T., primary, Zhou, Yumei, primary, Parent, Ephraim E., primary, Cai, Hancheng, primary, Knight, Joshua A., primary, Orme, Jacob, primary, Reynolds, Jordan, primary, Durham, William F., primary, Metz, Thomas M., primary, Meurice, Nathalie, primary, Edenfield, Brandy, primary, Alasonyalilar Demirer, Aylin, primary, Bilgili, Ahmet, primary, Hickman, Peyton G., primary, Pawlush, Matthew L., primary, Marlow, Laura, primary, Wickland, Daniel P., primary, Tan, Winston, primary, and Copland, John A., primary

Published
2024
Full Text
View/download PDF

43. Supplementary Figure 5 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer

Author

Kase, Adam M., primary, Gleba, Justyna, primary, Miller, James L., primary, Miller, Erin, primary, Petit, Joachim, primary, Barrett, Michael T., primary, Zhou, Yumei, primary, Parent, Ephraim E., primary, Cai, Hancheng, primary, Knight, Joshua A., primary, Orme, Jacob, primary, Reynolds, Jordan, primary, Durham, William F., primary, Metz, Thomas M., primary, Meurice, Nathalie, primary, Edenfield, Brandy, primary, Alasonyalilar Demirer, Aylin, primary, Bilgili, Ahmet, primary, Hickman, Peyton G., primary, Pawlush, Matthew L., primary, Marlow, Laura, primary, Wickland, Daniel P., primary, Tan, Winston, primary, and Copland, John A., primary

Published
2024
Full Text
View/download PDF

44. Supplementary Figure 3 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer

Author

Kase, Adam M., primary, Gleba, Justyna, primary, Miller, James L., primary, Miller, Erin, primary, Petit, Joachim, primary, Barrett, Michael T., primary, Zhou, Yumei, primary, Parent, Ephraim E., primary, Cai, Hancheng, primary, Knight, Joshua A., primary, Orme, Jacob, primary, Reynolds, Jordan, primary, Durham, William F., primary, Metz, Thomas M., primary, Meurice, Nathalie, primary, Edenfield, Brandy, primary, Alasonyalilar Demirer, Aylin, primary, Bilgili, Ahmet, primary, Hickman, Peyton G., primary, Pawlush, Matthew L., primary, Marlow, Laura, primary, Wickland, Daniel P., primary, Tan, Winston, primary, and Copland, John A., primary

Published
2024
Full Text
View/download PDF

45. Supplementary Figure 7 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer

Author

Kase, Adam M., primary, Gleba, Justyna, primary, Miller, James L., primary, Miller, Erin, primary, Petit, Joachim, primary, Barrett, Michael T., primary, Zhou, Yumei, primary, Parent, Ephraim E., primary, Cai, Hancheng, primary, Knight, Joshua A., primary, Orme, Jacob, primary, Reynolds, Jordan, primary, Durham, William F., primary, Metz, Thomas M., primary, Meurice, Nathalie, primary, Edenfield, Brandy, primary, Alasonyalilar Demirer, Aylin, primary, Bilgili, Ahmet, primary, Hickman, Peyton G., primary, Pawlush, Matthew L., primary, Marlow, Laura, primary, Wickland, Daniel P., primary, Tan, Winston, primary, and Copland, John A., primary

Published
2024
Full Text
View/download PDF

46. Supplementary Figure 2 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer

Author

Kase, Adam M., primary, Gleba, Justyna, primary, Miller, James L., primary, Miller, Erin, primary, Petit, Joachim, primary, Barrett, Michael T., primary, Zhou, Yumei, primary, Parent, Ephraim E., primary, Cai, Hancheng, primary, Knight, Joshua A., primary, Orme, Jacob, primary, Reynolds, Jordan, primary, Durham, William F., primary, Metz, Thomas M., primary, Meurice, Nathalie, primary, Edenfield, Brandy, primary, Alasonyalilar Demirer, Aylin, primary, Bilgili, Ahmet, primary, Hickman, Peyton G., primary, Pawlush, Matthew L., primary, Marlow, Laura, primary, Wickland, Daniel P., primary, Tan, Winston, primary, and Copland, John A., primary

Published
2024
Full Text
View/download PDF

48. Riskscapes and the Scaling of Digital Innovation: Trajectory Dynamics of Mobile Payments in Times of Crisis

Author

Barrett, Michael, Rannenberg, Kai, Editor-in-Chief, Soares Barbosa, Luís, Editorial Board Member, Goedicke, Michael, Editorial Board Member, Tatnall, Arthur, Editorial Board Member, Neuhold, Erich J., Editorial Board Member, Stiller, Burkhard, Editorial Board Member, Tröltzsch, Fredi, Editorial Board Member, Pries-Heje, Jan, Editorial Board Member, Kreps, David, Editorial Board Member, Reis, Ricardo, Editorial Board Member, Furnell, Steven, Editorial Board Member, Mercier-Laurent, Eunika, Editorial Board Member, Winckler, Marco, Editorial Board Member, Malaka, Rainer, Editorial Board Member, Bandi, Rajendra K., editor, C. R., Ranjini, editor, Klein, Stefan, editor, Madon, Shirin, editor, and Monteiro, Eric, editor

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results